Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2210

Sort by

Sort Order Select

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

No CpGs for AAVs?

Lindsey A. George

Blood (2021) 137 (6): 721–723.

https://doi.org/10.1182/blood.2020009285

Published: 2021

Journal Articles

Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease

Tomomi Toubai, John Magenau

Blood (2020) 136 (4): 429–440.

https://doi.org/10.1182/blood.2019000953

Published: 2020

Journal Articles

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano, Regis Peffault de Latour

Blood (2020) 135 (20): 1721–1722.

https://doi.org/10.1182/blood.2020005364

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat steroid-refractory acute graft-versus-host disease

Paul J. Martin

Blood (2020) 135 (19): 1630–1638.

https://doi.org/10.1182/blood.2019000960

Published: 2020

Includes: Supplemental data

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

The earlier the better: timely mitigation of CRS

Rayne H. Rouce

Blood (2019) 134 (24): 2119–2120.

https://doi.org/10.1182/blood.2019003618

Published: 2019

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

Glucocorticoids Induce the Maintenance and Expansion of an Immature CFU-E Erythroid Progenitor Population in Humans

Ryan Ashley, BS, MS, Hongxia Yan, MS, Nan Wang, PhD, John Hale, PhD, Brian M Dulmovits, MS, Julien Papoin, MS, Meagan Olive, Namrata Udeshi, PhD, Steven Carr, PhD, Adrianna Vlachos, MD, Jeffrey Michael M Lipton, MD PhD, Lydie M. Da Costa, MD PhD, Christopher D. Hillyer, MD, Sandrina Kinet, PhD, Naomi Taylor, MD PhD, Mohandas Narla, DSc, Anupama Narla, MD, Lionel Blanc, PhD

Blood (2019) 134 (Supplement_1): 943.

https://doi.org/10.1182/blood-2019-130710

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 714.

https://doi.org/10.1182/blood-2019-125639

Published: 2019

Journal Articles

Retrospective and Prospective Study of Childhood Autoimmune Hemolytic Anemia. a Preliminary Report from the Red Cell Working Group of the Paediatric Hemato-Oncology Italian Associations (AIEOP)

Blood (2019) 134 (Supplement_1): 947.

https://doi.org/10.1182/blood-2019-124735

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

James B. Bussel, MD, Waleed Ghanima, MD PhD, Yoshiaki Tomiyama, MD, Donald M. Arnold, MD, Drew Provan, MD, Ming Hou, MD PhD, Cristina Santoro, MD PhD, Serge Laborde, Alexandra Kruse, Caroline Kruse, Mervyn Morgan, Barbara Lovrencic, John Waller, PhD, Jens Haenig, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 1097.

https://doi.org/10.1182/blood-2019-130591

Published: 2019

Journal Articles

Gestational Thrombocytopenia: Insights into Mechanism from 3730 Pregnancies

Annemarie E Fogerty, MD, Walter Dzik, MD

Blood (2019) 134 (Supplement_1): 1092.

https://doi.org/10.1182/blood-2019-126045

Published: 2019

Journal Articles

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Shaun Fleming, MBBS,, Nicola Venn, BSc, John Reynolds, PhD, Uyen Nguyen, John Kwan, MBBS,FRACP,FRCPA, John Moore, MDFRACP,FRCPA, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Michael F. Leahy, MBChB, FRACP, FRCPath, FRCP, Matthew Greenwood, MBBS, FRACP, FRCPA, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Ashish Bajel, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Rosemary Sutton, BSc MSc PhD

Blood (2019) 134 (Supplement_1): 1300.

https://doi.org/10.1182/blood-2019-132048

Published: 2019

NARROW

A conceptual framework for managing iTTP

How I treat warm autoimmune hemolytic anemia

No CpGs for AAVs?

Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease

Ruxolitinib for steroid-resistant acute GVHD

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

How I treat steroid-refractory acute graft-versus-host disease

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

The earlier the better: timely mitigation of CRS

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Glucocorticoids Induce the Maintenance and Expansion of an Immature CFU-E Erythroid Progenitor Population in Humans

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Retrospective and Prospective Study of Childhood Autoimmune Hemolytic Anemia. a Preliminary Report from the Red Cell Working Group of the Paediatric Hemato-Oncology Italian Associations (AIEOP)

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

Gestational Thrombocytopenia: Insights into Mechanism from 3730 Pregnancies

Preliminary Minimal Residual Disease Analysis of the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 Study of Front-Line Blinatumomab with Chemotherapy in Adults with Ph Negative B-Cell Acute Lymphoblastic Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only